Clinical Trials Logo

Fibrosis clinical trials

View clinical trials related to Fibrosis.

Filter by:

NCT ID: NCT03161106 Withdrawn - Liver Cirrhosis Clinical Trials

To Assess Efficacy of Nutritional Therapy in Secondary Prophylaxis of Hepatic Encephalopathy Versus Lactulose in Patients With Liver Cirrhosis.

Start date: May 15, 2017
Phase: N/A
Study type: Interventional

The study will be conducted on patients attending /admitted to Department of Hepatology from April 2017 to December 2018 at ILBS, New Delhi . Clinical, anthropometric and biochemical assessment will be done by candidate, co-supervisors and supervisor. Patients in treatment group will receive nutritional therapy in the form of 30-kcal/kg/day and 1.5gm/kg/day protein with supplements. Other patients will continue diet that they were receiving before along with lactulose. Previous treatment and prophylaxis of variceal bleed any (endoscopic variceal ligation or beta blocker) will be continued as before. All subjects will be followed up every month for treatment compliance and for development of any complications.

NCT ID: NCT03058068 Withdrawn - Cystic Fibrosis Clinical Trials

Human MesenchymAl Stem Cells Infusion in Patients With Cystic Fibrosis

HAPI
Start date: December 2020
Phase: Phase 1
Study type: Interventional

A Safety Run-In will be followed by a Double-Blinded Randomized Phase. All subjects shall meet the inclusion/exclusion criteria, and will be evaluated prior to the scheduled infusion to establish baseline. There will be 3 subjects in the safety run-in phase and 15 subjects in the double-blinded phase.

NCT ID: NCT03005587 Withdrawn - Clinical trials for Acute Decompensation in Liver Cirrhosis

Impact of Acute Decompensation in Patients of Cirrhosis With or Without Prior Decompensation

Start date: December 31, 2016
Phase:
Study type: Observational

This a prospective observational study in Chronic Liver Disease patients admitted or seen in OPD, Department of Hepatology, Institute of Liver and Biliary Sciences, India. The study will be conducted in a period of three months starting September 2016 in sample size of 80 . A detailed proforma including history and examination and routine blood investigations will be noted. The patients will undergo close follow up at 0, 7, 15, 30, 45, 60, 90 days and similar activities will be repeated at every visit.

NCT ID: NCT02947516 Withdrawn - Fibrosis Clinical Trials

Comparison of EUS-Guided Liver Biopsy With Percutaneous Liver Biopsy

Start date: January 2017
Phase: N/A
Study type: Interventional

There are several ways to perform liver biopsies, including the percutaneous route (historical gold standard) and via endoscopic ultrasound (EUS) guidance. The primary aim of this study is to prospectively compare patients undergoing EUS-guided liver biopsies to patients undergoing percutaneous biopsy. The investigators hypothesize that (1) patients who are randomized to undergo EUS-guided liver biopsy will rate themselves as having less pain in the 48 hours following the procedure, and (2) will have comparable histologic yield to a 2:1 matched cohort of patients undergoing percutaneous liver biopsies.

NCT ID: NCT02899325 Withdrawn - Clinical trials for Hepatocellular Carcinoma

FDGal PET/CT to Detect Hepatocellular Carcinoma

Start date: October 2019
Phase:
Study type: Observational

Liver cancer is one of the leading causes of cancer death among Asian men. If diagnosed early the disease is treatable with surgery. Current conventional imaging modalities have limitations to early detection. This study proposes to use 18F-FGal and 18F-FDG PET/CT scans to compare the clinical efficacy of diagnosing hepatocellular carcinoma (a type of liver cancer) using these PET/CT scans.

NCT ID: NCT02868164 Withdrawn - Clinical trials for NASH Related Decompensated Cirrhosis

Fecal Microbiota Therapy Versus Standard Therapy in Decompensated NASH Related Cirrhosis: A Randomized Controlled Trial.

Start date: February 2018
Phase: N/A
Study type: Interventional

The study will be conducted in the Department of Hepatology, Institute of Liver & Biliary Sciences, New Delhi. As a part of this study history will be taken and clinical examination will be done. Subjects will be screened for diagnosis of NASH (Non Alcoholic Steatohepatitis) cirrhosis. If subjects are found to have NASH (Non Alcoholic Steatohepatitis) cirrhosis, they will be chosen to receive stool from healthy donor, which is voluntarily donated by a healthy donor related or unrelated to the subjects and the stool will be prepared using standard guidelines. The prepared sample of stool, about 50 ml will be instilled into proximal small intestine by way of a thin and soft tube inserted through nose. This administration of sample, 50 ml daily will occur once a month every month for 6 months. The liver function parameters will be assessed and thereafter at 1 month and 3 months & subjects will be clinically assessed for improvement or worsening.

NCT ID: NCT02837939 Withdrawn - Cirrhosis Clinical Trials

Transfer Factor Efficacy in the Management of Cirrhosis-associated Immune Dysfunction

IMUNO-HEGITO7
Start date: July 2016
Phase: Phase 2/Phase 3
Study type: Interventional

This study is aimed to assess the efficacy of Human derived Transfer factor ( T-lymphocytes homogenate that contains small molecular weight (10 kDa) molecules: various IFNs, ILs, chemokines, endorfins, heat shock proteins) in decreasing rate and/or severity of infections in acute or chronic decompensations of liver cirrhosis and acute on chronic liver failure..

NCT ID: NCT02824354 Withdrawn - Cirrhosis Clinical Trials

Nalmefene in Patients With Alcoholic Compensated Cirrhosis for the Treatment of Alcohol Dependence.

NalmeCir
Start date: December 1, 2018
Phase: Phase 3
Study type: Interventional

Nalmefene is the first drug to obtain Marketing Authorisation in France for reduction of alcohol consumption.

NCT ID: NCT02809248 Withdrawn - Clinical trials for Cirrhosis of the Liver

The Influence Cirrhosis of the Liver on the Coronary Re-stenosis (LTX- Stent Study)

Start date: July 2016
Phase: N/A
Study type: Interventional

The aim of the study is to choose an optimal stent and to get further knowledge about the mechanisms of the engraftment of a stent. The occurrence of a hyperplasia of neointima can be minimized by application of a coated stent and a concurrent safety four weekly dual thrombocytes therapy

NCT ID: NCT02739581 Withdrawn - Advanced Cirrhosis Clinical Trials

Efficacy and Safety of Endoscopic Variceal Ligation (EVL) Versus EVL Plus Non-selective B-blockers (NSBB) For Prevention of Variceal Rebleed and Non-bleed Related Complications in Patients With Advanced Cirrhosis

Start date: n/a
Phase: N/A
Study type: Interventional

The patients will be randomized into two groups 1. Endoscopic Variceal Ligation with Non Selective Beta Blocker 2. Placebo with Endoscopic Variceal Ligation